Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience

Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 7-10% of adults . The systemic treatment for moderate-to-severe AD was limited, but a new biologic drug (Dupilumab) was recently approved. It is a fully human monoclonal antibody directed against the alpha-subunit of the interleukin-4-receptor, blocking signalling of both Th2-cytokines IL-4 and IL-13. The effectiveness and safety was demonstrated in clinical trials , but these studies do not reflect conditions in daily practice.